Media Contact: Lissa Pavluk media@apellis.com (617) 977-6764
- July 9, 2024 Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting
- June 28, 2024 Apellis Plans to Seek Re-Examination Following Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU
- June 10, 2024 SYFOVRE® (pegcetacoplan injection) Preserved Visual Function at 36 Months in GALE Extension Study in Geographic Atrophy (GA)
- June 5, 2024 Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference
- May 24, 2024 Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress
- May 14, 2024 Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth Street
- May 7, 2024 Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results
- May 6, 2024 Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare Conference
- May 1, 2024 Apellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
- April 26, 2024 Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)
Displaying 1 - 10 of 287